Cencora, Inc. (NYSE:COR) Holdings Trimmed by FineMark National Bank & Trust

FineMark National Bank & Trust reduced its position in shares of Cencora, Inc. (NYSE:COR) by 0.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 8,998 shares of the company’s stock after selling 41 shares during the period. FineMark National Bank & Trust’s holdings in Cencora were worth $2,022,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. United Bank boosted its position in Cencora by 4.2% during the 3rd quarter. United Bank now owns 5,601 shares of the company’s stock worth $1,261,000 after acquiring an additional 225 shares during the period. Cerity Partners LLC lifted its position in shares of Cencora by 10.1% in the third quarter. Cerity Partners LLC now owns 39,457 shares of the company’s stock worth $8,881,000 after purchasing an additional 3,610 shares in the last quarter. Larson Financial Group LLC boosted its holdings in shares of Cencora by 146.1% during the third quarter. Larson Financial Group LLC now owns 1,900 shares of the company’s stock worth $428,000 after purchasing an additional 1,128 shares during the period. Daiwa Securities Group Inc. increased its stake in Cencora by 3.1% in the 3rd quarter. Daiwa Securities Group Inc. now owns 22,935 shares of the company’s stock valued at $5,162,000 after buying an additional 691 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Cencora in the 3rd quarter valued at approximately $974,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, CAO Lazarus Krikorian sold 2,000 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares in the company, valued at approximately $5,241,249.24. This trade represents a 9.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 4,970 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the transaction, the chief executive officer now owns 51,070 shares of the company’s stock, valued at approximately $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,970 shares of company stock valued at $2,998,670 in the last 90 days. 10.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Wells Fargo & Company boosted their target price on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research note on Friday, March 14th. StockNews.com raised Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. Finally, Evercore ISI increased their price objective on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus price target of $280.20.

Cencora Stock Up 0.3 %

COR opened at $268.31 on Wednesday. The firm has a market cap of $52.03 billion, a P/E ratio of 38.17, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The business has a 50 day moving average price of $251.80 and a 200 day moving average price of $240.46. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $271.08.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.82%. Cencora’s payout ratio is 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.